Survival rates have barely changed in 30 years.
World-first brain cancer clinical trials launched in Melbourne
A world-first clinical trial platform launching in Melbourne is set to transform research into new therapies for brain cancer and deliver more targeted, personalised treatment for patients.
The Brain-POP (brain perioperative) clinical trial platform will enable doctors to precisely see the effect of a new drug therapy on a patient’s brain cancer for the first time, by comparing tumour samples before and after treatment.
The new platform is led by The Brain Cancer Centre and research partners WEHI, The Royal Melbourne Hospital, Peter MacCallum Cancer Centre, The Royal Children’s Hospital and the University of Melbourne, with $16 million in funding support from the Victorian Government.
Working together to create a brighter future for patients and their families.
The Brain Cancer Centre
To deliver our vision, we need both a sense of urgency to improve the outcomes for brain cancer patients now and a commitment to long-term research that will provide life-changing treatments for future generations.
To be successful, a radically different approach to brain cancer research in Australia is required.
We will develop a system that:
- has CRITICAL MASS, significant funding, researchers and momentum driving us towards our mission;
- is COMPREHENSIVE, spanning discovery, translational research, clinical trials, data and tissue banking, and quality-of-life research;
- is COLLABORATIVE, harnessing the expertise of
multidisciplinary teams of scientists (biologists, chemists,
mathematicians, computer scientists and technologists)
and clinicians (oncologists, surgeons, radiation
oncologists and immunotherapists);
- is COLLEGIAL, where up-and-coming researchers are
attracted into the field to be inspired and mentored by
experienced scientists; and
- is COMMITTED to long-term research underpinned by